IDEAS home Printed from https://ideas.repec.org/a/plo/pgph00/0002834.html
   My bibliography  Save this article

The role of global health partnerships in vaccine equity: A scoping review

Author

Listed:
  • Charnele Nunes
  • Martin McKee
  • Natasha Howard

Abstract

The emergence of global health partnerships (GHPs) towards the end of the twentieth century reflected concerns about slow progress in access to essential medicines, including vaccines. These partnerships bring together governments, private philanthropic foundations, NGOs, and international agencies. Those in the vaccine field seek to incentivise the development and manufacture of new vaccines, raise funds to pay for them and develop and support systems to deliver them to those in need. These activities became more critical during the COVID-19 pandemic, with the COVAX Facility Initiative promoting global vaccine equity. This review identifies lessons from previous experiences with GHPs. Findings contribute to understanding the emergence of GHPs, the mechanisms they leverage to support global access to vaccines, and the inherent challenges associated with their implementation. Using Arksey and O’Malley’s method, we conducted a scoping review to identify and synthesise relevant articles. We analysed data thematically to identify barriers and opportunities for success. We included 68 eligible articles of 3,215 screened. Most (65 [95%]) were discussion or review articles describing partnerships or programmes they supported, and three (5%) were commentaries. Emerging themes included policy responses (e.g., immunisation mandates), different forms of partnerships arising in vaccine innovation (e.g., product development partnerships, public-private partnerships for access), and influence on global governance decision-making processes (e.g., the rising influence of foundations, diminishing authority of WHO, lack of accountability and transparency, creation of disease silos). If global health partnerships are to maximise their contributions, they should: (1) increase transparency, especially regarding their impacts; (2) address the need for health systems strengthening; and (3) address disincentives for cooperative vaccine research and development partnerships and encourage expansion of manufacturing capacity in low and middle-income countries.

Suggested Citation

  • Charnele Nunes & Martin McKee & Natasha Howard, 2024. "The role of global health partnerships in vaccine equity: A scoping review," PLOS Global Public Health, Public Library of Science, vol. 4(2), pages 1-16, February.
    • Handle: RePEc:plo:pgph00:0002834
    DOI: 10.1371/journal.pgph.0002834
    as

    Download full text from publisher

    File URL: https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0002834
    Download Restriction: no
    File URL: https://journals.plos.org/globalpublichealth/article/file?id=10.1371/journal.pgph.0002834&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pgph.0002834?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Muraskin, W., 2004. "The global alliance for vaccines and immunization: Is it a new model for effective public-private cooperation in international public health?," American Journal of Public Health, American Public Health Association, vol. 94(11), pages 1922-1925.
    2. Mrazek, Monique F. & Mossialos, Elias, 2003. "Stimulating pharmaceutical research and development for neglected diseases," Health Policy, Elsevier, vol. 64(1), pages 75-88, April.
    3. Joanna Chataway & Stefano Brusoni & Eugenia Cacciatori & Rebecca Hanlin & Luigi Orsenigo, 2007. "The International AIDS Vaccine Initiative (IAVI) in a Changing Landscape of Vaccine Development: A Public/Private Partnership as Knowledge Broker and Integrator," The European Journal of Development Research, Taylor and Francis Journals, vol. 19(1), pages 100-117.
    4. Buckup, Sebastian, 2008. "Global public–private partnerships against neglected diseases: building governance structures for effective outcomes," Health Economics, Policy and Law, Cambridge University Press, vol. 3(1), pages 31-50, January.
    5. Arne Ruckert & Ronald Labonté, 2014. "Public–private partnerships (s) in global health: the good, the bad and the ugly," Third World Quarterly, Taylor & Francis Journals, vol. 35(9), pages 1598-1614, October.
    6. Michael Stevenson, 2017. "PATH: pioneering innovation for global health at the public–private interface," Third World Quarterly, Taylor & Francis Journals, vol. 38(8), pages 1873-1893, August.
    7. Aerts, Céline & Sunyoto, Temmy & Tediosi, Fabrizio & Sicuri, Elisa, 2017. "Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature," Health Policy, Elsevier, vol. 121(7), pages 745-754.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(2), pages 185-208, April.
    2. Mueller-Langer, Frank, 2011. "Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting research?," MPRA Paper 40193, University Library of Munich, Germany.
    3. Veiga, Cássia Rita Pereira da & da Veiga, Claudimar Pereira & Mamédio, Diórgenes Falcão & Su, Zhaohui, 2024. "Innovative advances for neglected tropical disease (NTD): A global perspective from intellectual property," Technology in Society, Elsevier, vol. 78(C).
    4. Rutger Daems, PhD & Edith Maes, DBA, 2014. "Global Health Partnerships: Governance, Leadership, and Organizational Reform," Working Papers 2014/01, Maastricht School of Management.
    5. Theo Papaioannou, 2011. "Technological innovation, global justice and politics of development," Progress in Development Studies, , vol. 11(4), pages 321-338, July.
    6. Park, June & Chung, Eunbin, 2021. "Learning from past pandemic governance: Early response and Public-Private Partnerships in testing of COVID-19 in South Korea," World Development, Elsevier, vol. 137(C).
    7. repec:spo:wpmain:info:hdl:2441/401t6job098n79ch91o9giov9d is not listed on IDEAS
    8. Ohid Yaqub, 2018. "Variation in the dynamics and performance of industrial innovation: what can we learn from vaccines and HIV vaccines?," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 27(1), pages 173-187.
    9. Blume, Stuart & Zanders, Mariska, 2006. "Vaccine independence, local competences and globalisation: Lessons from the history of pertussis vaccines," Social Science & Medicine, Elsevier, vol. 63(7), pages 1825-1835, October.
    10. Perez, Marybel & von Schnurbein, Georg & Gehringer, Theresa, 2022. "Mitigating health policy fragmentation through interlocks. The networks between American and Swiss public-private partnerships," Health Policy, Elsevier, vol. 126(11), pages 1163-1172.
    11. Dosi, Giovanni & Lamperti, Francesco & Mazzucato, Mariana & Napoletano, Mauro & Roventini, Andrea, 2023. "Mission-oriented policies and the “Entrepreneurial State” at work: An agent-based exploration," Journal of Economic Dynamics and Control, Elsevier, vol. 151(C).
    12. Nannan Wang & Minxun Ma, 2021. "Public–private partnership as a tool for sustainable development – What literatures say?," Sustainable Development, John Wiley & Sons, Ltd., vol. 29(1), pages 243-258, January.
    13. Eric Asempah & Mary E. Wiktorowicz, 2023. "Understanding HPV Vaccination Policymaking in Rwanda: A Case of Health Prioritization and Public-Private-Partnership in a Low-Resource Setting," IJERPH, MDPI, vol. 20(21), pages 1-14, October.
    14. Mariana Mazzucato, 2015. "From Market Fixing to Market-Creating: A New Framework for Economic Policy," SPRU Working Paper Series 2015-25, SPRU - Science Policy Research Unit, University of Sussex Business School.
    15. Chataway, Joanna & Hanlin, Rebecca & Mugwagwa, Julius & Muraguri, Lois, 2010. "Global health social technologies: Reflections on evolving theories and landscapes," Research Policy, Elsevier, vol. 39(10), pages 1277-1288, December.
    16. Forman, Rebecca & Azzopardi-Muscat, Natasha & Kirkby, Victoria & Lessof, Suszy & Nathan, Naomi Limaro & Pastorino, Gabriele & Permanand, Govin & van Schalkwyk, May CI & Torbica, Aleksandra & Busse, Re, 2022. "Drawing light from the pandemic: Rethinking strategies for health policy and beyond," Health Policy, Elsevier, vol. 126(1), pages 1-6.
    17. Munira, Syarifah Liza & Fritzen, Scott A., 2007. "What influences government adoption of vaccines in developing countries? A policy process analysis," Social Science & Medicine, Elsevier, vol. 65(8), pages 1751-1764, October.
    18. Giovanni Dosi, 2021. "Some policy lessons from medical/therapeutic responses to the COVID-19 Crisis: A rich research system for knowledge generation and dysfunctional institutions for its exploitation," LEM Papers Series 2021/19, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
    19. Woodson, Thomas S., 2016. "Public private partnerships and emerging technologies: A look at nanomedicine for diseases of poverty," Research Policy, Elsevier, vol. 45(7), pages 1410-1418.
    20. Srinivas, Smita, 2006. "Industrial Development and Innovation: Some Lessons from Vaccine Procurement," World Development, Elsevier, vol. 34(10), pages 1742-1764, October.
    21. repec:hal:spmain:info:hdl:2441/401t6job098n79ch91o9giov9d is not listed on IDEAS
    22. Fonseca, Elize Massard da & Shadlen, Kenneth C. & Achcar, Helena de Moraes, 2023. "Vaccine technology transfer in a global health crisis: Actors, capabilities, and institutions," Research Policy, Elsevier, vol. 52(4).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pgph00:0002834. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: globalpubhealth (email available below). General contact details of provider: https://journals.plos.org/globalpublichealth .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.